Oncology – Page 34

Lenvatinib as a Promising Second-Line Therapy for Advanced Hepatocellular Carcinoma Post-Atezolizumab Plus Bevacizumab Failure: Insights from a Multicenter Phase II Trial

By MedXY 10/28/2025

A recent phase II trial demonstrates lenvatinib's efficacy and manageable safety as a second-line treatment for unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.

news Oncology

Alcohol’s Amplifying Effect on HBV-Related Liver Cancer: New Insights into Metabolic Reprogramming

By MedXY 10/27/2025

This article explores how alcohol consumption worsens HBV-induced hepatocellular carcinoma by promoting ER stress and lipid metabolic disturbances, highlighting potential therapeutic targets like LPLA2 and BMP.

news Oncology Urology

Rethinking Gleason Grade Group 1 Prostate Cancer: Insights from a Large-Scale Cohort Study

By MedXY 10/27/2025

This study highlights the heterogeneity of GG1 prostate cancer and its implications for classification and management strategies.

Gastroenterology news Oncology

Microbial Metabolism Dysfunction and Its Impact on Liver Injury After TACE in Hepatocellular Carcinoma

By MedXY 10/27/2025

This review explores how gut microbiota disturbances, especially L. reuteri and its metabolite ILA, influence post-TACE liver injury and prognosis in HCC patients, highlighting potential microbiota-targeted therapies.

Internal Medicine news Oncology Transplantation

Balancing Efficacy and Safety: Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients with Advanced Cancers

By MedXY 10/27/2025

This systematic review and meta-analysis evaluate cancer and graft outcomes in transplant recipients treated with immune checkpoint inhibitors, revealing differences by cancer type and potential strategies to reduce rejection risk.

news Oncology

Revolutionizing Early-Stage Cervical Cancer Management: Insights from the SENTIX Sentinel Lymph Node Trial

By MedXY 10/25/2025

The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.

news Oncology

Reevaluating Lymph Node Management in Early-Stage Cervical Cancer: Sentinel Biopsy Alone Shows Promise

By MedXY 10/25/2025

A large randomized trial finds sentinel lymph-node biopsy alone is noninferior to lymphadenectomy in early cervical cancer, with fewer complications and comparable survival outcomes.

news Oncology Respiratory

Emerging Promise of Sevabertinib for HER2-Mutant Non-Small-Cell Lung Cancer: A New Hope

By MedXY 10/25/2025

This article reviews recent clinical trial data showing sevabertinib's efficacy and safety in treating HER2-mutant NSCLC, highlighting its potential to fill an unmet therapeutic gap.

news Oncology Respiratory

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY 10/25/2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

news Oncology Respiratory

Advancing Treatment in EGFR-Mutant NSCLC: Efficacy of Amivantamab Plus Lazertinib Post-Resistances

By MedXY 10/25/2025

This article reviews the CHRYSALIS-2 cohort A study demonstrating the potential of combined amivantamab and lazertinib therapy in heavily pretreated EGFR-mutant NSCLC patients.

Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY 10/25/2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

news Oncology Respiratory

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY 10/25/2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

Dermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY 10/25/2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

Oncology Otorhinolaryngology

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY 10/25/2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting.

Oncology Pathology & Lab Medicine Urology

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

By MedXY 10/25/2025

This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immunotherapy after cystectomy.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Oncology Urology

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY 10/25/2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Oncology

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY 10/25/2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.